Objective: Asthma is a chronic inflammatory disorder of the airways with increasing worldwide prevalence. Despite treatment according to guidelines, a considerable proportion of patients with asthma remain symptomatic. Different potential therapeutic options for the treatment of these patients are currently in development and undergoing clinical trials, and it is important to regularly review their status. Data Sources: A search of ClinicalTrials.gov was performed and supported by a PubMed literature search and restricted to the previous 10 years to ensure currency of data. The results were manually filtered to identify relevant articles. Study Selections: Emerging therapies that are currently in phase 2 and 3 development include antiinterleukin agents (benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab, and mepolizumab), a chemoattractant receptor-homologous molecule expressed on a T-helper type 2 lymphocyte antagonist (OC000459), a phosphodiesterase-4 inhibitor (roflumilast), and long-acting muscarinic antagonists (glycopyrronium bromide, umeclidinium bromide, and tiotropium bromide). Results: The clinical trial program of the long-acting muscarinic antagonist tiotropium is currently the most advanced, with data available from different phase 2 and 3 studies. Results demonstrate that it is an efficacious add-on to at least inhaled corticosteroid maintenance therapy across severities of symptomatic asthma. Conclusion: The results of ongoing and future studies will help to determine whether these emerging therapeutic options will help address the unmet need for improvement in asthma management.
Introduction
Asthma is an inflammatory disease of the airways, with multifactorial pathophysiology. It is one of the most common chronic conditions, with a global prevalence of up to 18%, and is expected to affect approximately 400 million people worldwide by 2025. 1 Current Global Initiative for Asthma guidelines recommend stepwise treatment to achieve and maintain asthma control. 2 After initial treatment with inhaled corticosteroids (ICS), an increase in the ICS dose or the addition of another controller therapy, including long-acting b 2 -agonists (LABAs), leukotriene modifiers, or theophylline, is recommended to achieve control. In patients with more severe disease where control cannot be achieved add-on therapy with anti-immunoglobulin E or oral glucocorticosteroids is recommended.
Despite treatment according to current guidelines, such as the Global Initiative for Asthma guidelines, at least 40% of patients with asthma remain symptomatic. 3e6 In the United States, the Asthma Control Characteristics and Prevalence Survey Studies reported uncontrolled asthma in 58.8% and 49.7% of adult and pediatric patients, respectively, 7 whereas the European REcognise Asthma and LInk to Symptoms and Experience survey reported uncontrolled asthma in 45% of respondents. 8 Poorly controlled asthma puts patients at risk of future exacerbations and thus has a significant impact on patients' lifestyles and on the use of health care resources and health care costs. 9e13 It is important to recognize that although the degree to which a patient's asthma is controlled might be related to disease treatment or severity, it also might be affected by different variables, including comorbidities such as allergic rhinitis and gastroesophageal reflux, poor treatment adherence, incorrect inhaler technique, allergen exposure, or concurrent smoking. 14 There is an ongoing need for improvements in the management and control of asthma. This review examines recently published clinical data on emerging therapeutic options for the treatment of patients with symptomatic asthma.
Emerging Therapeutic Options for the Treatment of Asthma
Different promising therapeutic options are currently in development and undergoing clinical trials for the treatment of symptomatic asthma, including anti-interleukin (IL) agents, chemoattractant receptor-homologous molecules expressed on T-helper type 2 lymphocyte (CRT H 2) antagonists, phosphodiesterase-4 inhibitors, and long-acting muscarinic antagonists (LAMAs). The emerging anti-IL agents benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab, and mepolizumab, the CRT H 2 antagonist OC000459, the phosphodiesterase-4 inhibitor roflumilast, and the LAMAs glycopyrronium bromide, umeclidinium bromide, and tiotropium bromide were identified for inclusion based on recent literature.
Search Strategy
A search of ClinicalTrials.gov was performed using the drug names listed earlier AND asthma as search terms (Table 1) . A PubMed literature search also was performed using the Boolean string asthma* [title/abstract] AND drug name [title/abstract] AND clinical trial [ptyp] and was restricted to the previous 10 years to ensure currency of data (June 2015). The results were manually filtered to identify relevant articles or studies with data from well-designed clinical trials of the treatment of interest in human patients.
Anti-IL Agents in the Treatment of Asthma
Anti-IL agents are monoclonal anticytokine agents that decrease airway inflammation and prevent eosinophil activation. 15, 16 The literature search provided 16 publications relating to the anti-IL agents benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab, and mepolizumab (eTable 1A).
Benralizumab
An initial phase 1 study in 27 patients with asthma found that single-dose intravenous and multiple-dose subcutaneous benralizumab (antieIL-5) decreased airway, bone marrow, and peripheral blood eosinophil counts, with comparable safety profiles. 17 In a phase 2 study in 108 patients with acute asthma, a single dose of intravenous benralizumab was found to decrease the rate (1.82 vs 3.59 [total number of exacerbations per total duration of personyear follow-up], P ¼ .01) and severity (0.65 vs 1.62 [total number of exacerbations per total duration of person-year follow-up], P ¼ .02) of asthma exacerbations compared with placebo and had an acceptable safety profile. 18 Patients with severe asthma are currently being recruited for additional phase 3 studies (Table 1) .
Reslizumab
In a study of 106 patients with severe eosinophilic asthma, treatment with monthly reslizumab infusions (antieIL-5) showed a trend toward improved asthma control (P ¼ .0541), significantly decreased sputum eosinophils (P ¼ .0068), and significantly improved lung function, as measured by forced expiratory volume in 1 second (FEV 1 ; P ¼ .0023), percentage of predicted FEV 1 (P ¼ .0010), and forced vital capacity (FVC; P ¼ .0054), compared with placebo. 15 The results from the first phase 3 trials in 953 adult and adolescent patients (489 patients in study 1 and 464 patients in study 2) with moderate to severe eosinophilic asthma (NCT01287039 and NCT01285323) showed that monthly intravenous reslizumab significantly decreased the frequency of asthma exacerbations (P < .0001 in the 2 trials) and had a similar adverseevent profile compared with placebo. 19 Additional phase 2 and 3 trials of reslizumab in adult and pediatric patients with eosinophilic asthma are currently ongoing (Table 1) .
Dupilumab
Dupilumab (antieIL-4) showed efficacy in a 12-week phase 2 trial of 104 patients with moderate to severe eosinophilic asthma (NCT01312961). Significant decreases in the incidence of asthma exacerbations (P < .001) and significant improvements in most measurements of lung function (FEV 1 , P < .001) and asthma control (5-question Asthma Control Questionnaire [ACQ-5], P ¼ .001) were observed after once-weekly subcutaneous administration of 300 mg of dupilumab compared with placebo; dupilumab also was found to decrease biomarkers associated with T-helper type 2 (T H 2)-driven inflammation. 16 A phase 2 trial and follow-on phase 3 trial are currently ongoing to evaluate the efficacy and safety of different doses and treatment regimens of dupilumab in patients with moderate to severe asthma (Table 1) .
Brodalumab
In a phase 2 dose-ranging study in 302 adult patients with moderate to severe asthma (NCT01199289), no treatment differences were observed in 7-question ACQ (ACQ-7) scores, lung function, or asthma symptoms after subcutaneous brodalumab (antieIL-17) at 140, 210, or 280 mg or placebo. Prespecified subgroup analyses showed an improvement in ACQ-7 score beyond the minimal clinically important difference after 210 mg of brodalumab only (P ¼ .02; no adjustment for multiplicity) in patients with high bronchodilator reversibility (post-bronchodilator FEV 1 improvement !20%). 20 A second phase 2 study of brodalumab in patients with high bronchodilator reversibility is currently recruiting patients (Table 1) .
Lebrikizumab
Lebrikizumab (antieIL-13) at 250 mg, administered subcutaneously every 4 weeks, showed improved lung function in a phase 2 trial in 219 adult patients with inadequately controlled asthma despite medium-to high-dose ICS therapy (NCT00930163). Improvements in FEV 1 were significant compared with placebo (P ¼ .02), with greater improvements observed in patients with high serum-periostin levels. 21 In a second phase 2 trial in 212 patients with asthma not receiving ICS (NCT00971035), monthly subcutaneous administration of lebrikizumab at 125, 250, or 500 mg did not provide any meaningful improvements in lung function. 22 In a third phase 2 trial in 29 adult patients with mild allergic asthma (NCT00781443), monthly lebrikizumab treatment decreased the late asthmatic response (FEV 1 decrease !15% 2e12 hours after allergen challenge) by 48% compared with placebo, with exploratory analyses showing that patients with allergic asthma exhibited a greater decrease compared with those with nonallergic asthma. 23 Additional phase 2 studies of lebrikizumab in the treatment of asthma are ongoing, with phase 3 studies currently recruiting patients ( Table 1) .
Mepolizumab
Studies in patients with severe eosinophilic asthma showed that mepolizumab (antieIL-5) decreased exacerbation risk, improved quality of life, lowered eosinophil counts, improved asthma control, and improved lung function. In a phase 2 trial of 621 patients (NCT01000506), treatment with intravenous mepolizumab significantly lowered the rate of clinically significant exacerbations (48% decrease in the 75-mg group, 39% decrease in the 250-mg group, 52% decrease in the 750-mg group, P
.0005 for all comparisons) compared with placebo. 24 In a parallel-group trial of 61 patients with refractory eosinophilic asthma, monthly treatment with 750 mg of intravenous mepolizumab was associated with fewer severe exacerbations (P ¼ .02), lower blood (P < .001) and sputum (P ¼ .002) eosinophil counts, and significant improvements in quality of life (P ¼ .02) over 1 year compared with placebo, although no significant improvements in asthma symptoms, FEV 1 , or airway hyperresponsiveness were observed between treatment groups. 25 After cessation of mepolizumab treatment, an increase in blood eosinophil count, severe exacerbation frequency, and asthma symptoms was observed. 26 In a phase 2 parallel-group study of 20 patients with corticosteroid-dependent eosinophilic asthma (NCT00292877), the proportion of patients who experienced an asthma exacerbation was significantly decreased (P ¼ .008); there also were significant decreases in sputum (P ¼ .005) and blood (P ¼ .004) eosinophil levels and a significant improvement in asthma control (P ¼ .01) after 750 mg of intravenous mepolizumab every 4 weeks. 27 In a phase 3 study of 576 patients with severe eosinophilic asthma (NCT01691521), exacerbation rate was decreased by 47% and 53% and FEV 1 was increased by 100 and 98 mL (P < .05 for all comparisons) in patients receiving 75 mg of intravenous mepolizumab and 100 mg of subcutaneous mepolizumab monthly, respectively, with significant improvements also observed in asthma control. 28 In a second phase 3 study in 135 patients with severe eosinophilic asthma, after treatment with 100 mg of subcutaneous mepolizumab every 4 weeks, there was a 32% decrease in exacerbation rate and a decrease of 0.52 in ACQ-5 score, with the decrease in background ICS use 2.39 times greater than in the placebo treatment group. 29 Conversely, in a study by Flood-Page et al 30 of 362 patients with moderate symptomatic asthma, no significant clinical benefit was observed in lung function, rescue medication use, asthma symptoms, exacerbation rate, or quality of life after 3 intravenous infusions of 250 or 750 mg of mepolizumab at monthly intervals. In a subset of 37 patients from this study, significant decreases in sputum and blood eosinophils were observed after treatment with 250 and 750 mg of intravenous mepolizumab every 4 weeks (sputum, P ¼ .006 and P ¼ .004, respectively; blood, P < .001 for the 2 doses). Several additional phase 2 and 3 studies of mepolizumab in the treatment of patients with severe eosinophilic asthma are ongoing but have yet to report data ( Table 1) .
CRT H 2 Antagonists in the Treatment of Asthma
The CRT H 2 is a G-proteinecoupled receptor that mediates the activation of T H 2 lymphocytes, eosinophils, and basophils in response to prostaglandin D2. 31e33 Airway prostaglandin D2 levels are elevated in patients with asthma after an allergen challenge, suggesting a role in T H 2-mediated allergic inflammation, and therefore CRT H 2 antagonists might inhibit the activation of lymphocytes, eosinophils, and basophils and decrease the asthma allergic response. 32, 33 Three publications related to OC000459 were identified (eTable 1B), which is currently in phase 2 development (Table 1) .
OC000459
A phase 2 study of twice-daily OC000459 at 200 mg (NCT01057927) showed significantly improved quality of life (P ¼ .0113) and nocturnal symptoms (P ¼ .008) compared with placebo in 132 patients with moderate persistent asthma. Improvements in FEV 1 and sputum eosinophil count also were observed but were not statistically significant. 32 In a 2-way phase 2 crossover study of 21 steroid-naive patients with asthma (NCT01056692), treatment with twice-daily OC000459 at 200 mg was found to significantly inhibit the late asthmatic response to allergen challenge (P ¼ .018) and significantly reduce the post-allergen increase in sputum eosinophils (P ¼ .002); OC000459 treatment had no effect on the early asthmatic response to allergen challenge. 33 In a phase 2 dosefinding study of OC000459 once daily at 25 or 200 mg or twice daily at 100 mg in 519 patients with mild to moderate persistent asthma (NCT00890877), a significant improvement in FEV 1 was observed after treatment with the once-daily 25-mg dose (P ¼ .028). Significant improvements also were observed in ACQ-7 (P ¼ .001) and Asthma Quality of Life Questionnaire (P ¼ .002) scores, and there was a nonsignificantly lower incidence of exacerbations and a significant decrease in respiratory infections (P ¼ .003), in patients treated with OC000459 compared with placebo. 31 
Phosphodiesterase-4 Inhibitors in the Treatment of Asthma
Phosphodiesterases are involved in the degradation of cyclic adenosine monophosphate, a natural modulator of inflammation, which results in increased activity of inflammatory cells involved in the etiology of asthma, including T lymphocytes, eosinophils, macrophages, mast cells, monocytes, and neutrophils. 34e37 Inhibition of phosphodiesterase activity results in maintenance of cyclic adenosine monophosphate levels and subsequent downregulation of inflammatory processes in cells involved in the pathophysiology of asthma. 34e36 The PubMed literature search provided 6 publications related to roflumilast in the treatment of asthma (eTable 1C), with phase 2 and 3 trials ongoing (Table 1) . Roflumilast is approved for use in the treatment of chronic obstructive pulmonary disease, and anti-inflammatory effects have been observed in patients with asthma. 36e38
Roflumilast
Treatment with roflumilast has been shown to significantly improve the late asthmatic response compared with placebo. In a 2-period crossover study in 13 patients with mild allergic asthma, treatment with a single dose of 1,000 mg of roflumilast significantly improved the late asthmatic response to a histamine challenge (P ¼ .005). 37 A 3-period crossover study of 23 patients with mild asthma showed that once-daily treatment with 250 or 500 mg of roflumilast significantly decreased the early (P ¼ .0110 and P ¼ .0009, respectively) and late (P ¼ .0038 and P ¼ .0046, respectively) asthmatic reactions to allergens. 36 Further, in a phase 2 trial of 25 patients with mild allergic asthma (NCT01365533), 500 mg of roflumilast once daily inhibited the allergen-induced late-phase response (maximum percentage decrease in FEV 1 , P ¼ .02). 38 Improvements in lung function also have been reported after treatment with roflumilast. In a double-blinded, parallel-group trial of 693 adolescent and adult patients with mild to moderate asthma, treatment with once-daily roflumilast at 100, 250, or 500 mg significantly improved FEV 1 (P < .001 for all comparisons), with the 500-mg dose providing the greatest improvements. Morning and evening peak expiratory flow also were improved (P .006 for all comparisons) compared with placebo. 34 In a noninferiority study of 499 adolescent and adult patients with persistent asthma, once-daily roflumilast at 500 mg was found to provide comparable improvements in FEV 1 and FVC compared with treatment with twice-daily beclomethasone dipropionate at 200 mg. 35 In addition to showing efficacy in adult and adolescent patients with asthma, roflumilast has shown efficacy in pediatric patients with asthma. A 2-period ascending-dose study in 13 children and 12 adolescents with mild to moderate asthma found that roflumilast was well tolerated and that pharmacokinetic parameters were similar to those observed in adults. 39 
LAMAs in the Treatment of Asthma
The short-acting muscarinic antagonists ipratropium bromide and oxitropium bromide have been used in the treatment of asthma for several years; however, their widespread use has been limited because they are considered less effective than short-acting b 2 -agonists. 40 LAMAs block muscarinic acetylcholine receptors to impact on airway tone, smooth muscle contraction, mucus secretion, and vasodilation. 40e43 LAMAs have not been thoroughly investigated in asthma because of the perception that they provide little bronchodilation above that induced by LABAs. 44, 45 This view has now changed, and some LAMAs are being investigated in clinical trials of asthma, including glycopyrrolate, umeclidinium, and tiotropium 46, 47 (Table 1) .
A small phase 3 crossover study in 10 patients with asthma demonstrated that glycopyrrolate significantly prolonged bronchodilatation and bronchoprotection compared with ipratropium (eTable 1D). 48 A double-blinded crossover study of umeclidinium monotherapy in 350 patients with asthma (eTable 1D) found no conclusive therapeutic benefit in patients not receiving ICS. 49 However, the results of a double-blinded crossover study of ICS and umeclidinium combination therapy in 421 patients with asthma (eTable 1D) showed improvements in trough FEV 1 (26e55 mL) and morning (15.9e22.9 L/min) and evening (16.2e28.8 L/min) peak expiratory flow compared with ICS alone. 50 The tiotropium clinical trial program is currently the most advanced, and tiotropium, delivered through a soft-mist inhaler, has recently been incorporated into the Global Initiative for Asthma 2015 treatment guidelines as a recommended alternative therapy at steps 4 and 5 in adult patients with a history of exacerbations. 2 Data from 14 studies of tiotropium in asthma (eTable 1D) are reviewed below in more detail.
Tiotropium
Tiotropium, a long-acting anticholinergic bronchodilator, is currently approved by the US Food and Drug Administration for the treatment of patients with chronic obstructive pulmonary disease. 51, 52 It also has recently been approved for use in the treatment of asthma in the European Union and other countries worldwide. Further, it is currently under evaluation in the United States and other countries for the treatment of patients with asthma.
Early proof-of-concept studies in small numbers of patients indicated that tiotropium, delivered through the Spiriva HandiHaler device (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut), provides sustained bronchodilation and protection against bronchoconstriction. A study by Fardon et al 53 in 26 patients with severe asthma demonstrated that once-daily tiotropium at 18 mg provided significant improvements in lung function. Tiotropium at 18 mg also was shown to provide significant protection against methacholine challenge in a study of 10 patients with asthma and mild to moderate airway hyperresponsiveness. 54 Sposato et al 55 demonstrated that 18 mg of tiotropium provided greater protection against methacholine-induced bronchoconstriction than ipratropium bromide, with similar improvements in FEV 1 compared with oxitropium bromide, in a study of 44 patients with asthma.
In the large 3-way crossover Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) study in 210 patients with uncontrolled asthma (NCT00565266), once-daily tiotropium at 18 mg (through the Spiriva HandiHaler) significantly improved asthma symptoms (P < .001) and lung function (morning and evening peak expiratory flow, P < .001; FEV 1 , P ¼ .004) compared with a doubling of the ICS dose and was noninferior to salmeterol in patients with symptomatic asthma. 56 A prespecified analysis of the TALC study data showed that a large number of patients who responded to treatment with albuterol and had increased airway obstruction demonstrated improved lung function after treatment with tiotropium. 57 Recent studies in patients with symptomatic asthma have evaluated the efficacy of once-daily tiotropium delivered by the Respimat Soft Mist inhaler (hereinafter referred to as tiotropium Respimat; Boehringer Ingelheim, Ingelheim am Rhein, Germany; Fig 1) . The Respimat inhaler provides increased aerosol production time compared with pressurized metered-dose inhalers and drypowder inhalers, which could benefit patients with low inspiratory capacity or poor timing of inhalation to actuation. 58 Phase 2 trials have examined the efficacy and safety of different doses and dosing regimens of tiotropium Respimat. Tiotropium at 10 and 5 mg as add-on to high-dose ICS plus LABA, taken each morning (NCT00365560), significantly improved peak FEV 1 (P < .0001 for all comparisons) and trough FEV 1 (P < .0004 for all comparisons) compared with placebo in 107 patients with severe symptomatic asthma. Adverse events were balanced across treatment groups, apart from dry mouth, which had a higher incidence in the 10-mg tiotropium treatment group (6.8%; 1.9% in the 5-mg group and 1.0% in the placebo group). 59 Once-daily evening dosing of tiotropium at 5, 2.5, and 1.25 mg as add-on to medium-dose ICS in 149 patients with moderate persistent asthma (NCT01233284) resulted in statistically significant improvements in lung function (peak FEV 1 within 3 hours after the dose [peak FEV 1(0e3h) ], trough FEV 1 , FEV 1 area under the curve [AUC] [0e3h] , peak FVC [0e3h] , trough FVC, and FVC AUC [0e3h] ), with the 5-mg dose associated with the greatest improvements in all measurements. 60 Improvements in lung function were found to be significant and equally well sustained for oncedaily tiotropium at 5 mg (morning dosing) and twice daily at 2.5 mg (morning and evening dosing) as add-on to medium-dose ICS in a study of 94 patients with moderate symptomatic asthma (NCT01152450). 61 In a study of 388 patients with moderate asthma with the B16-Arg/Arg genotype (NCT00350207), treatment with a once-daily evening dose of 5 mg of tiotropium was found to be superior to matching placebo (P <.05) and as efficacious as twice-daily salmeterol (P ¼ .002) at maintaining improved lung function. 62 Phase 3 trials have examined the efficacy, safety, and tolerability of tiotropium Respimat in patients across severities of symptomatic asthma, as defined by ICS dose. In 2 randomized, double-blinded, 48-week, parallel-group trials with identical designs (NCT00772538 and NCT00776984), 912 patients with poorly controlled asthma received 5 mg of tiotropium once daily or placebo each morning as add-on to high-dose ICS plus LABA. Treatment with 5 mg of tiotropium significantly improved peak and trough FEV 1 (P .01 for the 2 end points in the 2 trials) and increased the time to the first severe asthma exacerbation by 56 days, with a decrease of 21% in the risk of experiencing a severe exacerbation (pooled data, P ¼ .03), compared with placebo. 63 (NCT01172808 and NCT01172821), 2,100 patients with moderate symptomatic asthma received 5 or 2.5 mg of tiotropium, or salmeterol or placebo, as add-on to medium-dose ICS. Because the results were highly comparable between studies, the investigators presented pooled data. Significant improvements in peak and trough FEV 1 were observed (P < .001 for all comparisons), with a larger proportion of ACQ-7 responders observed after 24 weeks of treatment with the tiotropium doses (5 mg, odds ratio 1.32, P ¼ .035; 2.5 mg, odds ratio 1.33, P ¼ .031), compared with placebo. 64 Tiotropium Respimat was found to have safety and tolerability that were comparable with those of placebo in all trials in which they were assessed. 59e65 In a long-term study of 5 or 2.5 mg of tiotropium or placebo once daily as add-on to medium-dose ICS with or without a LABA each evening in 285 Japanese patients (NCT01340209), the safety and tolerability (primary end point of the study) of tiotropium were found to be comparable with those of placebo. 65 The first results from studies of tiotropium Respimat in adolescents and children are available. A phase 2, incomplete-crossover, dose-ranging study of 5, 2.5, and 1.25 mg of tiotropium as add-on to medium-dose ICS with or without a leukotriene receptor antagonist was conducted in 105 adolescent patients 12 to 17 years old with moderate symptomatic asthma (NCT01122680). Measurements of peak FEV 1(0e3h) (P ¼ .0004), trough FEV 1 (P < .0001), and FEV 1 AUC (0e3h) (P ¼ .001) were significantly improved after treatment with 5 mg of tiotropium. 66 In a second phase 2 study of identical design in 101 children 6 to 11 years old with moderate symptomatic asthma (NCT01383499), significant improvements in measurements of peak FEV 1(0e3h) (P < .001 for all comparisons), trough FEV 1 (P < .005 for all comparisons), and FEV 1 AUC (0e3h) (P < .005 for all comparisons) were observed after treatment with all doses of tiotropium. 67 As in the trials in adult patients, tiotropium was found to have comparable safety and tolerability as placebo. 66, 67 Further phase 2 and 3 studies of tiotropium as add-on to at least ICS in adolescents and children as young as 1 year are in progress.
Conclusions
There is currently an unmet need in the treatment of asthma, with a significant proportion of patients remaining symptomatic despite treatment according to guidelines. Different additional therapeutic options are undergoing development for use in the treatment of asthma, including anti-IL agents, CRT H 2 antagonists, phosphodiesterase-4 inhibitors, and LAMAs.
The tiotropium clinical trial program is currently the most advanced, with published data from different phase 2 and 3 randomized clinical trials in patients with asthma. Data from studies in adult and adolescent patients with asthma have shown that tiotropium is an efficacious add-on to at least ICS maintenance therapy, with comparable safety and tolerability as placebo. Tiotropium could offer an alternative treatment option, particularly for patients for whom current treatments are unsuitable or ineffective. In adult patients with severe asthma and a history of exacerbations, tiotropium has recently been recommended as an alternative therapeutic option at Global Initiative for Asthma steps 4 and 5. 2 It should be considered that clinical trial efficacy is distinct from real-life effectiveness. A recent retrospective study in 2,042 patients with asthma highlighted that primary care physicians in the United Kingdom have been prescribing LAMAs for the treatment of asthma since 2002, predominantly as add-on therapy in older patients with poorly controlled asthma despite good treatment compliance, particularly in those who were current or former smokers. 68 In this real-life patient population, the addition of tiotropium, as 18 mg through the HandiHaler device (93%) or 5 mg through the Respimat Soft Mist inhaler (7%), provided a significant decrease in the incidence of exacerbations and antibiotic prescriptions for lower respiratory tract infections and a significant increase in asthma control during the following year. Additional large studies of data from real-life asthma populations will help to improve individualized patient care and will be useful to help determine the position of tiotropium in relation to current asthma treatment guidelines. Once fully indicated by regulatory authorities and incorporated into asthma treatment guidelines across age groups and disease severities, the use of tiotropium in the treatment of asthma might become more widespread, given its availability in pharmacies and physicians' familiarity with using it to treat patients with chronic obstructive pulmonary disease.
Cost-effectiveness also is an important consideration in relation to real-life utility of treatments and deciding their relative place in therapeutic guidelines. This is particularly the case for biological therapies that target specific cytokines, which might require biomarker analyses to select the correct patients for treatment; such biomarker analyses are not required before treatment with tiotropium. In the first analysis of the cost-effectiveness of tiotropium, Willson et al 69 concluded that tiotropium provided a costeffective treatment option in adult patients with severe asthma, as add-on to high-dose ICS plus LABA therapy. Further costeffectiveness analyses, across age ranges and severities of asthma, could help to determine whether tiotropium add-on therapy provides an affordable treatment option that addresses the current unmet need in asthma treatment.
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